Company news: Pfizer, OraSure

Share this article:
The FDA panel's tepid embrace of Pfizer's RA drug tofacitinib last week has been matched by an equally anemic payer reaction. A study by the research firm Reimbursement Intelligence told MM&M criticism of the drug's less-than-impressive ability to delay progression encouraged payers to put the drug out of immediate reach. CEO Rhonda Greenapple said 37% of polled payers said they would require patients to fail on at least two anti-TNFs before approving tofacitinib. Greenapple said that percentage was 25% before the FDA review.

Pfizer's renal cell carcinoma drug Torisel (temsirolimus) failed to prove it could extend life for cancer patients on the cancer drug Sutent (sunitinib malate). The company announced Wednesday that the treatment “did not meet the primary endpoint of prolonging progression-free survival when compared to sorafenib.” The company said in a statement that the results do not discount the drug's value. “Torisel continues to be an important part of Pfizer's portfolio of therapies for advanced kidney cancer,” Mace Rothenberg, SVP of clinical development and medical affairs, said in a statement.

An oral home HIV test got a 17-0 endorsement from an FDA advisory panel Tuesday. The OraQuick home test uses saliva instead of blood to test for HIV and takes 20 minutes to return results, reported the New York Times. OraSure's multi-component kit includes a hard case that serves a dual purpose: it houses the testing equipment and props up vials to make it easier for users to mix components. It also includes pre- and post-testing pamphlets, as well as instructions. It does not have the same accuracy rate as professional tests, said the Times.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.